Informations:
Erreur:
ID
31752
Description
A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00912899
Lien
https://clinicaltrials.gov/show/NCT00912899
Mots-clés
Versions (1)
- 25/09/2018 25/09/2018 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
25 septembre 2018
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Refractory Multiple Myeloma NCT00912899
Eligibility Refractory Multiple Myeloma NCT00912899
- StudyEvent: Eligibility
Similar models
Eligibility Refractory Multiple Myeloma NCT00912899
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Multiple Myeloma Advanced
Item
advanced multiple myeloma.
boolean
C0026764 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0205179 (UMLS CUI [1,2])
Disease Progression | Status post Prior Therapy Course Quantity | Steroids Quantity | Biological Response Modifiers Quantity | Alkylating Agents Quantity | bortezomib | Velcade
Item
progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (imid), one alkylator, and bortezomib (velcade®).
boolean
C0242656 (UMLS CUI [1])
C0231290 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C0750729 (UMLS CUI [2,3])
C1265611 (UMLS CUI [2,4])
C0038317 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0005525 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0002073 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C1176309 (UMLS CUI [6])
C1174739 (UMLS CUI [7])
C0231290 (UMLS CUI [2,1])
C1514463 (UMLS CUI [2,2])
C0750729 (UMLS CUI [2,3])
C1265611 (UMLS CUI [2,4])
C0038317 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0005525 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0002073 (UMLS CUI [5,1])
C1265611 (UMLS CUI [5,2])
C1176309 (UMLS CUI [6])
C1174739 (UMLS CUI [7])
ECOG performance status
Item
ecog performance status of either 0 or 1.
boolean
C1520224 (UMLS CUI [1])
Prior Chemotherapy | Antimitotic Agents
Item
prior chemotherapy with antimicrotubule agents
boolean
C1514457 (UMLS CUI [1])
C0003379 (UMLS CUI [2])
C0003379 (UMLS CUI [2])
Metastatic malignant neoplasm to brain | Secondary malignant neoplasm of spinal cord
Item
metastasis involving the brain or spinal cord
boolean
C0220650 (UMLS CUI [1])
C0347016 (UMLS CUI [2])
C0347016 (UMLS CUI [2])
Lung disease | Heart Disease
Item
clinically significant lung or heart disease
boolean
C0024115 (UMLS CUI [1])
C0018799 (UMLS CUI [2])
C0018799 (UMLS CUI [2])
Electrocardiogram abnormal
Item
abnormal electrocardiogram
boolean
C0522055 (UMLS CUI [1])
Eligibility Criteria Additional
Item
please note that there are additional inclusion and exclusion criteria. the study center will determine if you meet all of the criteria.
boolean
C1516637 (UMLS CUI [1,1])
C1524062 (UMLS CUI [1,2])
C1524062 (UMLS CUI [1,2])
Study Subject Participation Status | Counseling Research Personnel
Item
site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. you can then decide whether or not you wish to participate. if you do not qualify for the trial, site personnel will explain the reasons.
boolean
C2348568 (UMLS CUI [1])
C0010210 (UMLS CUI [2,1])
C0035173 (UMLS CUI [2,2])
C0010210 (UMLS CUI [2,1])
C0035173 (UMLS CUI [2,2])